Results 71 to 80 of about 278,227 (245)

Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report

open access: yesThyroid Research
Background Rituximab, an anti-CD20 monoclonal antibody that depletes B-cells, is a potential second-line treatment for moderate-to-severe active Thyroid Eye Disease that is resistant to steroids.
Mirco Armenti   +6 more
doaj   +1 more source

Graves' ophthalmopathy [PDF]

open access: yes, 2009
A 40-year-old woman who recently received a diagnosis of Graves' disease comes for a follow-up visit. She has been taking methimazole, at a dose of 10 mg daily, and is now euthyroid, but for the past 3 months, she has had bothersome eye symptoms ...
Bartalena, Luigi   +1 more
core   +1 more source

Single‐Cell RNA Sequencing of Thyroid Tissues Reveals Pathogenesis of Graves' Disease

open access: yesAdvanced Science, Volume 13, Issue 1, 5 January 2026.
Using single‐cell RNA sequencing and TCR profiling, this study constructed an immune cell atlas in thyroid tissue of Graves’ disease (GD), revealing dominant IFN‐γ‐secreting CD4+ T cells, expanded Tph and CD11c+ B cells, and enriched T/NK cells. Notably, GD thyroid follicular cells (TFCs) activated γδ T cells, which recruited cDC1 cells, suggesting a ...
Xiaoyi Zhou   +18 more
wiley   +1 more source

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy

open access: yesFrontiers in Endocrinology, 2021
Graves’ orbitopathy (GO), also known as thyroid-associated ophthalmopathy, is the most common ocular abnormality of Graves’ disease. It is a disfiguring, invalidating, and potentially blinding orbital disease mediated by an interlocking and complicated ...
S. Fang   +4 more
semanticscholar   +1 more source

Association of Individual or Family History of Autoimmune Disease With Future Development of Type 1 Diabetes

open access: yesDiabetes/Metabolism Research and Reviews, Volume 42, Issue 1, January 2026.
ABSTRACT Timely diagnosis of type 1 diabetes (T1D), especially in high‐risk populations, is crucial for preventing serious health complications. T1D is a chronic progressive autoimmune disease that has presymptomatic stages that can be identified through the detection of islet autoantibodies. Given that T1D is associated with other autoimmune diseases,
Nick Thomas   +8 more
wiley   +1 more source

Effectiveness of Selenium Supplementation in the Treatment of Graves–Basedow Disease: A Scoping Review

open access: yesMedical Sciences
Background: Graves–Basedow disease (GBD) is an autoimmune thyroid disorder characterized by loss of tolerance to the thyrotropin receptor, with clinical manifestations such as a hyperadrenergic state, goiter, orbitopathy, and myxedema, inter alia ...
Hernando Vargas-Uricoechea   +5 more
doaj   +1 more source

Graves’ disease and exophthalmos — a mask for meningioma

open access: yesEndokrynologia Polska, 2021
Not required for Clinical Vignette.
Kamila Mitka   +3 more
doaj   +1 more source

Differential Gene Expression Profiling of Orbital Adipose Tissue in Thyroid Orbitopathy [PDF]

open access: yes, 2015
Published under a Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/legalcode)PURPOSE. We aimed to determine differentially expressed genes relevant to orbital inflammation and orbital fat
Burdon, Kathryn Penelope   +11 more
core   +1 more source

Steroid-Resistant Graves’ Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience

open access: yesJournal of Clinical Medicine, 2021
This study aimed to assess the effectiveness and safety of tocilizumab use for the treatment of active steroid-resistant Graves’ orbitopathy (GO). A retrospective longitudinal study was conducted by reviewing the medical records at a single center ...
J. V. Pérez-Moreiras   +3 more
semanticscholar   +1 more source

PDGFRα+DPP4+ Fibroblasts‐Macrophage Crosstalk Induces Orbital Fibrosis in Treatment‐Resistant Thyroid Eye Disease via the GAS6‐AXL Pathway

open access: yesAdvanced Science, Volume 12, Issue 45, December 4, 2025.
This study elucidates macrophage‐induced orbital fibrosis in TED via the GAS6‐AXL pathway, a treatment‐resistant disorder lacking non‐surgical therapies. Using a novel patient cell‐derived orthotopic animal model of orbital fibrosis for TED, we repurpose an existing fibrosis therapy, addressing the absence of stable models and offering a potential ...
Lu Cheng   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy